AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RMD

Farrell Michael J. sold $968K of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $193.96 ($0.97M total) on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Jun 9, 2026, 6:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Neutral
medium confidence
Mentioned
$RMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

The newest fact is the CEO/chairman’s open-market sale amount and execution date, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but 10b5-1 sales usually carry limited fundamental information.

03

What to watch

Check whether there were multiple consecutive insider sales or changes in trading patterns; a single 10b5-1 sale is often statistically noisy.

Relevance 4/10Novelty 5/10Timing: filed June 9; sale executed June 8

Background

The article is an SEC Form 4 insider transaction disclosure for ResMed (RMD).

Company-level read

Ticker impact

$RMDNeutralMedium confidence
Context

ResMed insider Form 4 shows CEO/chairman Michael Farrell sold 4,991 shares for ~$968K on a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect should be short-lived unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan and provides no new operational/regulatory information.

Market effects

Sector

No direct sector read-through; this is company-specific insider liquidity/positioning.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect scheduled diversification rather than bearish expectations; traders may ignore it absent follow-on selling or fundamentals.

Key entities

  • issuer
    ResMed Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Farrell Michael J.

    Chairman and CEO who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com